Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
AssigneesShanghai XBH Biotechnology Co., LTD., GV20 Therapeutics LLC
InventorsXiaole Liu, Xihao Hu, Tengfei Xiao
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided. The methods and compositions are used for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.
Claims28
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an IGSF8 (Immuno Globulin Super Family 8) antagonist.
Use of an IGSF8 antagonist for treating cancer in a subject.
An antibody which specifically bind IGSF8 for use in a method of treating cancer, preferably through stimulating T cell and/or NK cell activation.
A monoclonal antibody or an antigen-binding fragment thereof specific for IGSF8, wherein said monoclonal antibody comprises:
- (1) a heavy chain variable region (HCVR), comprising HCVR CDR1-CDR3 sequences of any one of antibodies C1-C29, such as C1-C12;
- and,
- (2) a light chain variable region (LCVR), comprising LCVR CDR1-CDR3 sequences of said any one of antibodies C1-C29, such as C1-C12.
A method of stimulating T cell and/or NK cell activation in a tumor microenviroment (TME), the method comprising contacting said T cell and/or NK cell with an IGSF8 (Immuno Globulin Super Family 8) antagonist, such as an antibody or antigen-binding fragment thereof that specifically binds IGSF8.
Dependencies are inferred from the claim text.